Lapatinib Base CAS 231277-92-2 Purity ≥99.0% (HPLC)

Lapatinib is a new drug for targeted therapy of breast cancer developed by GlaxoSmithKline, UK. It is a tyrosine kinase inhibitor that can effectively inhibit human epidermal growth factor receptor -1(ErbB1) and human epidermal growth factor receptor -2(ErbB2) tyrosine kinase activity. It is unique in that it can function in a variety of ways so that breast cancer cells cannot receive the signals needed for growth. The mechanism of action is to inhibit the ATP sites of EGFR(ErbB-1) and HER2(ErbB-2) in cells to prevent phosphorylation and activation of tumor cells, and block down-regulation signals through homogenous and heterogeneous dimers of EGFR(ErbB-1) and HER2(ErbB-1). Molecular targeted therapy for breast cancer refers to the treatment of oncogenes and related expression products related to the occurrence and development of breast cancer. Molecular targeted drugs inhibit or kill tumor cells by blocking signal transduction in tumor cells or related cells to control changes in cell gene expression. on March 14, 2007, the U.S. food and drug administration approved the combination of lapatinib and xeloda (capecitabine) for the treatment of advanced or metastatic breast cancer patients overexpressed by human epidermal factor receptor 2(ErbB2) and treated with anthracyclines, paclitaxel and trastuzumab. Clinical trials show that this product also has good clinical effects for HER2 breast cancer patients who have developed drug resistance to Roche's Herceptin (Herceptin). lapatinib is a new targeted anticancer drug. It can act on Her-1 and Her-2 targets at the same time. The biological effect of this mode of action on the proliferation and growth of tumor cells is far greater than that of only one target. The so-called targeted therapeutic drugs refer to drugs that use certain receptors, genes or key proteins as targets to kill related tumor cells in a targeted manner.